ABVC receives Nasdaq delisting notice for low equity; raises $436K in stock sale

ABVC BIOPHARMA, INC.

Nasdaq notified ABVC on April 24 that stockholders' equity of $723,959 is below the $2.5M minimum for continued listing.
ABVC has 45 days to submit a compliance plan; if accepted, it may have until Oct 21, 2025 to regain compliance.
Sold 724,372 common shares to 15 non-U.S. persons for gross proceeds of ~$436,000 under Regulation S.
Each purchaser agreed to transfer voting rights to Chairman Eugene Jiang via a Voting Rights Proxy Agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.